Skip to main content
永顺生物 logo

永顺生物 — Investor Relations & Filings

Ticker · 920729 Beijing Stock Exchange Manufacturing
Open in API
Filings indexed 388 across all filing types
Latest filing 2025-04-27 Capital/Financing Update
Country CN China
Listing Beijing Stock Exchange 920729

About 永顺生物

https://www.winsun-gd.com/

Guangdong Winsun Bio-Pharmaceutical Co., Ltd. is a specialized enterprise focused on the research, development, production, and distribution of veterinary biological products. The company primarily develops vaccines for livestock and poultry, with a significant emphasis on swine and avian health. Its product portfolio includes live and inactivated vaccines targeting major diseases such as classical swine fever, porcine reproductive and respiratory syndrome (PRRS), and avian influenza. Winsun Bio-Pharmaceutical leverages advanced biotechnology to provide comprehensive animal disease prevention and control solutions. The company maintains a strong focus on technological innovation and quality management, operating multiple GMP-certified production lines to ensure the efficacy and safety of its biological preparations. Its research initiatives often involve collaborations with academic institutions to advance veterinary medicine and support the animal husbandry sector.

Recent filings

Filing Released Lang Actions
关于公司使用自有资金购买稳健型理财产品的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement by Guangdong Yongshun Biopharmaceutical Co., Ltd. regarding the company's use of its own funds to purchase stable financial products. It includes details about the purpose, amount, decision-making process, risk analysis, and impact on the company. The document is relatively short (1270 characters) and focuses on a specific financing activity rather than a full financial report or earnings release. It is not a report itself but an announcement about a capital use decision. Therefore, it fits best under Capital/Financing Update (CAP).
2025-04-27 Chinese
天健会计师事务所（特殊普通合伙）关于广东永顺生物制药股份有限公司募集资金年度存放与使用情况鉴证报告
Regulatory Filings
2025-04-27 Chinese
2024年度董事会审计委员会履职情况报告
Audit Report / Information Classification · 95% confidence The document is titled as the "2024年度董事会审计委员会履职情况报告" which translates to "2024 Annual Report on the Board Audit Committee's Performance." It details the audit committee's activities, meetings, evaluations of external auditors, internal control assessments, and overall performance for the year 2024. The content focuses on the audit committee's oversight and supervisory role rather than presenting full financial statements or a comprehensive annual report. It is a specialized report related to audit committee activities and their fulfillment of duties, which aligns with the category of Audit Report / Information (AR). The document length is 2598 characters, which is relatively short but contains substantive content about audit committee work rather than just an announcement or certification. Therefore, it is not a Regulatory Filing (RNS) or Report Publication Announcement (RPA). Hence, the best fit is AR (Audit Report / Information). FY 2024
2025-04-27 Chinese
关于召开2024年年度股东会通知公告（提供网络投票）
AGM Information Classification · 100% confidence The document is a notice announcing the convening of the 2024 Annual General Meeting (AGM) of Guangdong Yongshun Biopharmaceutical Co., Ltd. It details the meeting date, voting methods (including online voting), agenda items to be discussed and voted on, including reports and proposals related to the 2024 annual report, financial budget, related party transactions, and board member changes. The document does not contain the actual reports or financial statements but rather serves as an official announcement and invitation for shareholders to attend and vote at the AGM. The presence of detailed agenda items and meeting logistics confirms it is an AGM Information document, not the reports themselves or voting results. The document length (6245 characters) supports it being a full notice rather than a brief announcement. Therefore, the correct classification is AGM Information (AGM-R).
2025-04-27 Chinese
内部控制自我评价报告
Audit Report / Information Classification · 95% confidence The document is titled "内部控制自我评价报告" which translates to "Internal Control Self-Evaluation Report." It is issued by Guangdong Yongshun Biopharmaceutical Co., Ltd. and dated April 28, 2025. The content details the company's internal control evaluation for the year ending December 31, 2024, including governance structure, risk assessment, control activities, information and communication, and internal supervision. It discusses the effectiveness of internal controls over financial reporting and non-financial reporting, defect identification standards, and corrective actions. The document is a comprehensive report on internal control evaluation rather than an announcement or a brief summary. It does not fit categories like Annual Report (10-K), Earnings Release, or Regulatory Filings. It is a standalone report focused on internal control audit and evaluation, which aligns with the definition of Audit Report / Information (AR). The document length (8039 characters) supports it being a full report rather than a short announcement. Therefore, the appropriate classification is AR with high confidence. FY 2024
2025-04-27 Chinese
2024年年度权益分派预案公告
Notice of Dividend Amount Classification · 95% confidence The document is titled as a "2024 Annual Equity Distribution Plan Announcement" from Guangdong Yongshun Biopharmaceutical Co., Ltd. It discusses the company's plan to distribute cash dividends for the 2024 fiscal year, referencing the audited 2024 annual report and the company's retained earnings as of December 31, 2024. The document details the dividend amount, the board and supervisory committee approvals, and the company's articles of association regarding profit distribution. It also mentions that the plan requires approval at the 2024 annual shareholders meeting. The document is an announcement of a dividend distribution plan, not the full annual report or the actual dividend payment notice. It is a formal announcement of the equity distribution proposal to shareholders, including relevant legal and procedural information. Given the content and purpose, this fits best under the category "Notice of Dividend Amount (DIV)", which covers announcements of dividend amounts, payment dates, and details for shareholders. The document length is 3826 characters, which is consistent with an announcement rather than a full report. Therefore, the classification is DIV with high confidence.
2025-04-27 Chinese

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.